Takeda announces positive results for mezagitamab in Phase 2 ITP study
Takeda Pharmaceutical Company Limited has disclosed favorable top-line outcomes from a Phase 2, randomized, double-blind, placebo-controlled trial, assessing the safety, tolerability, and efficacy of mezagitamab ... Read More
Oscotec reports positive results from cevidoplenib phase 2 trial in ITP
Oscotec has reported positive results from the phase 2 clinical trial of its SYK inhibitor cevidoplenib in patients with immune thrombocytopenia (ITP) who did not ... Read More
Sobi begins avatrombopag phase 3 trial in immune thrombocytopenia in pediatrics
Swedish Orphan Biovitrum (Sobi) said that the first patient has been dosed with Doptelet (avatrombopag) in a phase 3 trial for the treatment of immune ... Read More
FDA greenlights Amgen’s Nplate for pediatric immune thrombocytopenia
Amgen’s Nplate (romiplostim) has received US Food and Drug Administration (FDA) approval for treating pediatric patients with immune thrombocytopenia (ITP). This latest approval extends the ... Read More